Correction of Experimental Retinal Ischemia by l-Isomer of Ethylmethylhydroxypyridine Malate

Abstract

An important task of pharmacology and ophtalmology is to find specific and highly effective agents for correcting retinal ischemia. The objective of this study is to increase the effectiveness of pharmacological correction of retinal ischemia by using new 3-hydroxypyridine derivative–l-isomer of ethylmethylhydroxypyridine malate. A modification to the retinal ischemia-reperfusion model was used, in which an increase in intraocular pressure is carried out by mechanical pressure (110 mmHg) to the front chamber of the eye for 30 min. The protective effects of l-isomer of ethylmethylhydroxypyridine malate in comparison with Emoxipine as pretreatment, with parabulbar injection, based on the model of retinal ischemia-reperfusion, were estimated by the changes in the ratio of the amplitudes of the a- and b-waves of electroretinography (the b/a coefficient) and ophthalmoscopy. The use of l-isomer of ethylmethylhydroxypyridine malate improves the retinal electrophysiological state after 72 h of reperfusion; in the group of rats treated with l-isomer of ethylmethylhydroxypyridine malate, the coefficient b/a was reliably increased by 9.5%, p < 0.05, in comparison with animals treated with Emoxipine, and by 91.7%, p < 0.05, in comparison with the group with no treatment. Furthermore, it prevents the development of ischemic changes in the retina observed in ophthalmoscopy to a greater extent than Emoxipine.

Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate

“…A retinal ischemia-reperfusion model was used according to the method previously published by us [16,21], in which an increase in IOP to 110 mmHg is carried out within 30 min by applying mechanical pressure to the anterior eye chamber. Retinal ischemia was simulated under general anesthesia (chloral hydrate, 300 mg/kg of rat body mass, i.p.…”

“…Emoxipine (methylethylpiridinol) is used to treat subconjunctival hemorrhages, intraocular hemorrhages, and angioretinopathy [20]. The presence of 3-hydroxypyridine pharmacophore in a structure provides a complex of antioxidant and membranotropic effects, as well as the reduction of glutamate excitotoxicity [21,22].…”

“…Treatment of ischemic retinal conditions is done using angioprotectors, antioxidants, fibrinolytics, and anticoagulants [21]. Due to the instability effects when carrying out drug therapy, it is necessary to seek out more effective methods to increase resistance to retinal ischemia [26][27][28].…”

“…Thus, the relevance of the research is the study of the retinoprotective effects of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate along with the evaluation of the eye fundus state, retinal microcirculation level, and electrophysiological state of the retina, specifically, the b/a coefficient [16,21,29,30] in an experiment when retinal ischemia-reperfusion is corrected.…”

Studies to Elucidate the Effects of Furostanol Glycosides from Dioscorea deltoidea Cell Culture in a Rat Model of Endothelial Dysfunction

“…Differences were determined at a 0.05 significance level. Statistical analyses were performed using Statistica 10.0 software [22]. Funding: This research received no external funding.…”